drugset / Trial / NCT00624858

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

NCT00624858

Phase 2 Completed 25 enrolled Orexigen Therapeutics, Inc
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.

Timeline

Start
2008-01
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 360 mg
Subject Naltrexone Small molecule 32 mg

Indications